共 30 条
- [1] Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trialBRITISH JOURNAL OF CANCER, 2024, 130 (01) : 43 - 52Jo, Jung HyunKim, Yong-TaeChoi, Ho SoonKim, Ho GakLee, Hong SikChoi, Young WooKim, Dong UkLee, Kwang HyuckKim, Eui JooHan, Joung-HoLee, Seung OkPark, Chang-HwanChoi, Eun KwangKim, Jae WooCho, Jae YongLee, Woo JinMoon, Hyungsik RogerPark, Mi-SukKim, SangjaeSong, Si Young
- [2] Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trialBritish Journal of Cancer, 2024, 130 : 163 - 163Jung Hyun JoYong-Tae KimHo Soon ChoiHo Gak KimHong Sik LeeYoung Woo ChoiDong Uk KimKwang Hyuck LeeEui Joo KimJoung-Ho HanSeung Ok LeeChang-Hwan ParkEun Kwang ChoiJae Woo KimJae Yong ChoWoo Jin LeeHyungsik Roger MoonMi-Suk ParkSangjae KimSi Young Song
- [3] Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial (Oct, 10.1038/s41416-023-02474-w, 2023)BRITISH JOURNAL OF CANCER, 2023, 130 (1) : 163 - 163Jo, Jung HyunKim, Yong-TaeChoi, Ho SoonKim, Ho GakLee, Hong SikChoi, Young WooKim, Dong UkLee, Kwang HyuckKim, Eui JooHan, Joung-HoLee, Seung OkPark, Chang-HwanChoi, Eun KwangKim, Jae WooCho, Jae YongLee, Woo JinMoon, Hyungsik RogerPark, Mi-SukKim, SangjaeSong, Si Young
- [4] KG 4/2015: A randomized, controlled, multicenter, open-label phase III clinical trial of GV1001 with gemcitabine/capecitabine in previous untreated, eotaxin-high patients with advanced pancreatic ductal adenocarcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Jo, Jung HyunKim, Yong-TaeChoi, Ho SoonKim, Ho GakLee, Hong SikChoi, Young WooKim, Dong UkLee, Kwang HyuckKim, Eui JooHan, Jeong HoLee, Seung OkPark, Chang-HwanChoi, Eun KwangLee, Kyong JooCho, Jae YongLee, Woo JinSong, Si Young
- [5] Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trialLANCET ONCOLOGY, 2014, 15 (08): : 829 - 840Middleton, GarySilcocks, PaulCox, TrevorValle, JuanWadsley, JonathanPropper, DavidCoxon, FareedaRoss, PaulMadhusudan, SrinivasanRoques, TomCunningham, DavidFalk, StephenWadd, NickHarrison, MarkCorrie, PippaIveson, TimRobinson, AngusMcAdam, KarenEatock, MartinEvans, JeffArcher, CarolineHickish, TamasGarcia-Alonso, AngelNicolson, MarianneSteward, WilliamAnthoney, AlanGreenhalf, WilliamShaw, VictoriaCostello, EithneNaisbitt, DeanRawcliffe, CharlotteNanson, GemmaNeoptolemos, John
- [6] Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trialLANCET ONCOLOGY, 2013, 14 (06): : 490 - 499Lordick, FlorianKang, Yoon-KooChung, Hyun-CheolSalman, PamelaOh, Sang CheulBodoky, GyoergyKurteva, GalinaVolovat, ConstantinMoiseyenko, Vladimir M.Gorbunova, VeraPark, Joon OhSawaki, AkiraCelik, IlhanGoette, HeikoMelezinkova, HelenaMoehler, Markus
- [7] Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialLANCET ONCOLOGY, 2013, 14 (06): : 481 - 489Waddell, TomChau, IanCunningham, DavidGonzalez, DavidFrances, AliciaOkines, ClareWotherspoon, AndrewSaffery, ClaireMiddleton, GaryWadsley, JonathanFerry, DavidMansoor, WasatCrosby, TomCoxon, FareedaSmith, DavidWaters, JustinIveson, TimothyFalk, StephenSlater, SarahPeckitt, ClareBarbachano, Yolanda
- [8] Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trialLANCET, 2017, 389 (10073): : 1011 - 1024Neoptolemos, John P.Palmer, Daniel H.Ghaneh, PaulaPsarelli, Eftychia E.Valle, Juan W.Halloran, Christopher M.Faluyi, OlusolaO'Reilly, Derek A.Cunningham, DavidWadsley, JonathanDarby, SuzanneMeyer, TimGillmore, RoopinderAnthoney, AlanLind, PehrGlimelius, BengtFalk, StephenIzbicki, Jakob R.Middleton, Gary WilliamCummins, SebastianRoss, Paul J.Wasan, HarpreetMcDonald, AlecCrosby, TomMa, Yuk TingPatel, KinnariSherriff, DavidSoomal, RubinBorg, DavidSothi, SharmilaHammel, PascalHackert, ThiloJackson, RichardBuechler, Markus W.
- [9] Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trialLANCET ONCOLOGY, 2013, 14 (11): : 1077 - 1085Cunningham, DavidLang, IstvanMarcuello, EugenioLorusso, VitoOcvirk, JanjaShin, Dong BokJonker, DerekOsborne, StuartAndre, NikoWaterkamp, DanielSaunders, Mark P.
- [10] Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trialECLINICALMEDICINE, 2023, 58Bekaii-Saab, TaniosOkusaka, TakujiGoldstein, DavidOh, Do-YounUeno, MakotoIoka, TatsuyaFang, WeijiaAnderson, Eric C.Noel, Marcus S.Reni, MicheleChoi, Hye JinGoldberg, Jonathan S.Oh, Sang CheulLi, Chung-PinTabernero, JosepLi, JianFoos, EmmaOh, CindyVan Cutsem, Eric